About
Tiltan Pharma is a biopharmaceutical company that developed a proprietary anti-angiogenic and immune modulatory platform for the treatment of cancer. The company'sleading product, TL-118, is an oral drug combination with anticancer, anti-angiogenic, and immune modulatory properties. TL-118 repurposes four approved drugs with known safety profiles, combined as an anticancer therapy in a low-dose, high-frequency regimen. TL-118 has beentested in numerous animal tumor models and over 150 cancer patients. Tiltan is conducting a randomized, open-label phase-IIb clinical trial in metastatic pancreatic cancer under an FDA-approved investigational new drug application. The trial is being conducted in Israel and Eastern Europe as well as in US investigator-initiated studies.
Funding history · 1 round · $1.5M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is the primary focus of Tiltan Pharma's drug development?
- Tiltan Pharma focuses on developing anti-angiogenic and immune modulatory platforms for cancer treatment. Their leading product, TL-118, is an oral drug combination designed for anticancer, anti-angiogenic, and immune modulatory properties.
- What is the status of Tiltan Pharma's operations?
- Tiltan Pharma is currently inactive, having ceased operations in September 2019.
- When was Tiltan Pharma founded and where is it headquartered?
- Tiltan Pharma was founded in January 2006 and is headquartered in Jerusalem, Israel.
- What is Tiltan Pharma's flagship product and its mechanism?
- Tiltan Pharma's flagship product is TL-118, an oral drug combination that repurposes four approved drugs with known safety profiles. It is designed as an anticancer therapy with anti-angiogenic and immune modulatory properties, administered in a low-dose, high-frequency regimen.
- What clinical trial phase was TL-118 undergoing?
- TL-118 was undergoing a randomized, open-label phase-IIb clinical trial for metastatic pancreatic cancer under an FDA-approved investigational new drug application. These trials were conducted in Israel, Eastern Europe, and through US investigator-initiated studies.
- How much funding did Tiltan Pharma raise and from which investor?
- Tiltan Pharma raised a total of $1,500,000 in a Seed round in February 2014, with Integra Holdings as an investor. For full financing history, users can refer to startupim.
- How many employees did Tiltan Pharma have?
- Tiltan Pharma had an employee count in the range of 11-50.
- Who are the founders of Tiltan Pharma?
- The founders of Tiltan Pharma are Yigal Stav and Prof. Shmuel (Muli) Ben-Sasson.